                         SEQUENCE LISTING

<110>  ELI LILLY AND COMPANY
 
<120>  ANTI-CD20- / ANTI-BAFF BISPECIFIC ANTIBODIES

<130>  X20443

<150>  62/142,706
<151>  2015-04-03

<160>  22    

<170>  PatentIn version 3.5

<210>  1
<211>  715
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  First Polypeptide of the exemplified bispecific antibody of Table
       1

<400>  1

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Phe Ser Gly His 
            20                  25                  30          


Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Ala Arg Asp Ile Leu Thr Gly Tyr Leu Tyr Tyr Tyr Asp His 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 
        115                 120                 125             


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 
    130                 135                 140                 


Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu 
145                 150                 155                 160 


Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu 
                165                 170                 175     


Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
            180                 185                 190         


Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser 
        195                 200                 205             


Gly Ser Gly Thr Asp Ser Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 
    210                 215                 220                 


Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn His Pro Arg Thr 
225                 230                 235                 240 


Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly 
                245                 250                 255     


Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Gln Ser 
            260                 265                 270         


Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys 
        275                 280                 285             


Gly Ser Gly Arg Thr Phe Thr Ser Tyr Asn Met His Trp Val Arg Gln 
    290                 295                 300                 


Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ala Ile Tyr Pro Leu Thr 
305                 310                 315                 320 


Gly Asp Thr Ser Tyr Asn Gln Lys Ser Lys Leu Gln Val Thr Ile Ser 
                325                 330                 335     


Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys 
            340                 345                 350         


Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Ser Thr Tyr Val Gly 
        355                 360                 365             


Gly Asp Trp Gln Phe Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val 
    370                 375                 380                 


Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 
385                 390                 395                 400 


Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 
                405                 410                 415     


Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 
            420                 425                 430         


Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 
        435                 440                 445             


Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 
    450                 455                 460                 


Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 
465                 470                 475                 480 


Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 
                485                 490                 495     


Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 
            500                 505                 510         


Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 
        515                 520                 525             


Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 
    530                 535                 540                 


Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 
545                 550                 555                 560 


Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 
                565                 570                 575     


Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 
            580                 585                 590         


Ser Asn Lys Ala Leu Pro Ala Pro Glu Glu Lys Thr Ile Ser Lys Gln 
        595                 600                 605             


Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 
    610                 615                 620                 


Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 
625                 630                 635                 640 


Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 
                645                 650                 655     


Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 
            660                 665                 670         


Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 
        675                 680                 685             


Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 
    690                 695                 700                 


Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 
705                 710                 715 


<210>  2
<211>  213
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Second Polypeptide of the exemplified bispecific antibody of 
       Table 1

<400>  2

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Pro Tyr Ile 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
        35                  40                  45              


Ala Thr Ser Ala Leu Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu 
65                  70                  75                  80  


Asp Phe Ala Val Tyr Tyr Cys Gln Gln Trp Leu Ser His Pro Pro Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 
            100                 105                 110         


Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 
        115                 120                 125             


Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 
    130                 135                 140                 


Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 
145                 150                 155                 160 


Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 
                165                 170                 175     


Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 
            180                 185                 190         


Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 
        195                 200                 205             


Asn Arg Gly Glu Cys 
    210             


<210>  3
<211>  2145
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  DNA Seq. Encoding the First Polypeptide of the exemplified 
       bispecific antibody of Table 1

<400>  3
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc       60

acctgcactg tctctggagg ctccttcagt ggtcattact ggagctggat tcgccagccc      120

ccagggaagt gtctggagtg gattggggaa atcaatcata gtggaagcac caactacaac      180

ccgtccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg      240

aaactgagct ctgtgaccgc cgcggacacg gctgtgtatt actgtgcgag aggggctaga      300

gatattttga ctggttatct atactactat gaccattggg gccagggaac cctggtcacc      360

gtctcctcag ggggaggggg cagcggagga ggcggatcgg gcggaggagg aagtggaggc      420

ggaggcagcg aaattgtgtt gacgcagtct ccagccaccc tgtctttgtc tcctggggaa      480

agagccaccc tctcctgcag ggccagtcag agtgttagcc gctacttagc ctggtaccag      540

cagaaacctg gccaggctcc caggctcctc atctatgatg catccaacag ggccactggc      600

atcccagcca ggttcagtgg cagtgggtct gggacagact ccactctcac catcagcagc      660

ctagagcctg aagattttgc agtttattac tgtcagcagc gtagcaacca ccctcggacg      720

ttcggctgtg ggaccaaggt ggaaatcaaa ggcggtggtg gcagcggcgg aggcggatcc      780

ggcggaggtg gaagcgaggt gcagctggtg cagtctggag cagaggtgaa aaagcccggg      840

gagtctctga agatctcctg taagggttct ggccgtacat ttaccagtta caatatgcac      900

tgggtgcgcc agatgcccgg gaaaggcctg gagtggatgg gggctattta tcccttgacg      960

ggtgatactt cctacaatca gaagtcgaaa ctccaggtca ccatctcagc cgacaagtcc     1020

atcagcaccg cctacctgca gtggagcagc ctgaaggcct cggacaccgc catgtattac     1080

tgtgcgagat cgacttacgt gggcggtgac tggcagttcg atgtctgggg caaggggacc     1140

acggtcaccg tctcctcagc ctccaccaag ggcccatcgg tcttcccgct agcaccctcc     1200

tccaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga ctacttcccc     1260

gaaccggtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca caccttcccg     1320

gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc     1380

agcttgggca cccagaccta catctgcaac gtgaatcaca agcccagcaa caccaaggtg     1440

gacaagaaag ttgagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca     1500

cctgaactcc tggggggacc gtcagtcttc ctcttccccc caaaacctaa ggacaccctc     1560

atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct     1620

gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg     1680

cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag     1740

gactggctga atggcaagga gtacaagtgc aaggtctcca acaaagccct cccagccccc     1800

gaggagaaaa ccatctccaa acagaaaggg cagccccgag aaccacaggt gtacaccctg     1860

cccccatccc gggacgagct gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc     1920

ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac     1980

aagaccacgc cccccgtgct ggactccgac ggctccttct tcctctatag caagctcacc     2040

gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct     2100

ctgcacaacc actacacaca gaagagcctc tccctgtctc cgggt                     2145


<210>  4
<211>  639
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  DNA Seq. Encoding the Second Polypeptide of the exemplified 
       bispecific antibody of Table 1

<400>  4
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagggccacc       60

ctctcctgca gggccagctc aagtgtaccg tacatccact ggtaccagca gaaacctggc      120

caggctccca ggctcctcat ctatgccaca tccgccctgg cttctggcat cccagacagg      180

ttcagtggca gtgggtctgg gacagacttc actctcacca tcagcagact ggagcctgaa      240

gattttgcag tgtattactg tcagcagtgg ctgagtcatc cacccacttt tggccagggg      300

accaagctgg agatcaaacg aactgtggct gcaccatctg tcttcatctt cccgccatct      360

gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc      420

agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag      480

agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg      540

agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg      600

agctcgcccg tcacaaagag cttcaacagg ggagagtgc                             639


<210>  5
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCVR1 of the exemplified bispecific antibody of Table 1

<400>  5

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Phe Ser Gly His 
            20                  25                  30          


Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Cys Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly Ala Arg Asp Ile Leu Thr Gly Tyr Leu Tyr Tyr Tyr Asp His 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120             


<210>  6
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCVR2 of the exemplified bispecific antibody of Table 1

<400>  6

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Arg Thr Phe Thr Ser Tyr 
            20                  25                  30          


Asn Met His Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Ala Ile Tyr Pro Leu Thr Gly Asp Thr Ser Tyr Asn Gln Lys Ser 
    50                  55                  60                  


Lys Leu Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Thr Tyr Val Gly Gly Asp Trp Gln Phe Asp Val Trp Gly 
            100                 105                 110         


Lys Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  7
<211>  106
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCVR1 of the exemplified bispecific antibody of Table 1

<400>  7

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Pro Tyr Ile 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 
        35                  40                  45              


Ala Thr Ser Ala Leu Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu 
65                  70                  75                  80  


Asp Phe Ala Val Tyr Tyr Cys Gln Gln Trp Leu Ser His Pro Pro Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  8
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCVR2 of the exemplified bispecific antibody of Table 1

<400>  8

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Ser Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn His Pro Arg 
                85                  90                  95      


Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  9
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR1 of the exemplified bispecific antibody of Table 1

<400>  9

Lys Gly Ser Gly Arg Thr Phe Thr Ser Tyr Asn Met His 
1               5                   10              


<210>  10
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR2 of the exemplified bispecific antibody of Table 1

<400>  10

Ala Ile Tyr Pro Leu Thr Gly Asp Thr Ser Tyr Asn Gln Lys Ser Lys 
1               5                   10                  15      


Leu 
    


<210>  11
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR3 of the exemplified bispecific antibody of Table 1

<400>  11

Ala Arg Ser Thr Tyr Val Gly Gly Asp Trp Gln Phe Asp Val 
1               5                   10                  


<210>  12
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR4 of the exemplified bispecific antibody of Table 1

<400>  12

Thr Val Ser Gly Gly Ser Phe Ser Gly His Tyr Trp Ser 
1               5                   10              


<210>  13
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR5 of the exemplified bispecific antibody of Table 1

<400>  13

Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  14
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HCDR6 of the exemplified bispecific antibody of Table 1

<400>  14

Ala Arg Gly Ala Arg Asp Ile Leu Thr Gly Tyr Leu Tyr Tyr Tyr Asp 
1               5                   10                  15      


His 
    


<210>  15
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR1 of the exemplified bispecific antibody of Table 1

<400>  15

Arg Ala Ser Ser Ser Val Pro Tyr Ile His 
1               5                   10  


<210>  16
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR2 of the exemplified bispecific antibody of Table 1

<400>  16

Tyr Ala Thr Ser Ala Leu Ala Ser 
1               5               


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR3 of the exemplified bispecific antibody of Table 1

<400>  17

Gln Gln Trp Leu Ser His Pro Pro Thr 
1               5                   


<210>  18
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR4 of the exemplified bispecific antibody of Table 1

<400>  18

Arg Ala Ser Gln Ser Val Ser Arg Tyr Leu Ala 
1               5                   10      


<210>  19
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR5 of the exemplified bispecific antibody of Table 1

<400>  19

Tyr Asp Ala Ser Asn Arg Ala Thr 
1               5               


<210>  20
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LCDR6 of the exemplified bispecific antibody of Table 1

<400>  20

Gln Gln Arg Ser Asn His Pro Arg Thr 
1               5                   


<210>  21
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Polypeptide Linker 1 of the exemplified bispecific antibody of 
       Table 1

<400>  21

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
1               5                   10                  15      


Gly Gly Gly Ser 
            20  


<210>  22
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Polypeptide Linker 2 of the exemplified bispecific antibody of 
       Table 1

<400>  22

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


